We thank David Galloway, ELS, for expert editorial review; Tad McKeon for data collection; and Julie Groff for preparing the figures.
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia
Article first published online: 1 MAR 2013
Copyright © 2013 American Cancer Society
Volume 119, Issue 11, pages 2061–2066, 1 June 2013
How to Cite
Rubnitz, J. E., Campbell, P., Zhou, Y., Sandlund, J. T., Jeha, S., Ribeiro, R. C., Inaba, H., Bhojwani, D., Relling, M. V., Howard, S. C., Campana, D. and Pui, C.-H. (2013), Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer, 119: 2061–2066. doi: 10.1002/cncr.28026
Ching-Hon Pui is an American Cancer Society Professor.
- Issue published online: 20 MAY 2013
- Article first published online: 1 MAR 2013
- Manuscript Accepted: 2 FEB 2013
- Manuscript Revised: 1 FEB 2013
- Manuscript Received: 18 DEC 2012
- acute lymphoblastic leukemia;
Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies. However, the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic leukemia (ALL) treated in recent trials is unknown.
Outcomes of 399 patients aged ≤18 years with newly diagnosed ALL who were enrolled in the Total Therapy XV study at St. Jude Children's Research Hospital were analyzed according to ALC at the end of remission induction therapy.
An ALC ≥500 cells/μL was significantly more prevalent among patients with B-lineage ALL, in those with favorable presenting features, and in those who achieved negative minimal residual disease (MRD) status on day 43 of treatment. Both overall survival (OS) and event-free survival (EFS) were superior among patients with higher ALC, but only the association with OS was statistically significant in a univariate analysis. In multivariable analyses, ALC was not a significant predictor of outcome after controlling for age, leukocyte count, lineage, risk group, and MRD status at the end of induction (P > .1 for all comparisons). However, among MRD-negative patients, those with low ALC had a 5-year OS rate of 84.2% ± 8.9% versus 97.3% ± 1.0% for patients with higher ALC (P = .036).
ALC at the end of induction is related to favorable presenting features and good initial treatment response but does not independently predict outcome in the context of contemporary, MRD-guided therapy. Cancer 2013;119:2061–2066. © 2013 American Cancer Society.